The estimated Net Worth of Alpna Seth is at least $2.07 Milión dollars as of 9 November 2020. Alpna Seth owns over 5,023 units of Seagen Inc stock worth over $1,639,095 and over the last 7 years he sold SGEN stock worth over $0. In addition, he makes $433,036 as Independent Director at Seagen Inc.
Alpna has made over 1 trades of the Seagen Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 5,023 units of SGEN stock worth $732,102 on 9 November 2020.
The largest trade he's ever made was exercising 5,023 units of Seagen Inc stock on 9 November 2020 worth over $732,102. On average, Alpna trades about 279 units every 0 days since 2017. As of 9 November 2020 he still owns at least 7,162 units of Seagen Inc stock.
You can see the complete history of Alpna Seth stock trades at the bottom of the page.
Dr. Alpna Seth Ph.D. serves as Independent Director of the Company. Dr. Seth has over 20 years of global experience in the biotechnology industry. Having held a range of leadership roles around the globe, Dr. Seth brings a breadth of experience in drug development, commercial, international operations and general management.
As the Independent Director of Seagen Inc, the total compensation of Alpna Seth at Seagen Inc is $433,036. There are 15 executives at Seagen Inc getting paid more, with Clay Siegall having the highest compensation of $14,521,500.
Alpna Seth is 56, he's been the Independent Director of Seagen Inc since 2018. There are 13 older and 7 younger executives at Seagen Inc. The oldest executive at Seagen Inc is Marc Lippman, 75, who is the Independent Director.
Alpna's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro... a Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: